Import restrictions have been changed to help ensure people
with prescriptions for cannabis-based products for medicinal
use do not have their treatment delayed or interrupted.
The changes will help patients with conditions such as rare,
serious forms of epilepsy or multiple sclerosis.
Licensed wholesalers will now be able to:
Most cannabis-based medicines are imported from foreign
countries. Export restrictions mean it can take weeks or
months for the drugs to reach the patients in the UK. For
example, in Canada, an export certificate can take 4 to 8
weeks.
In addition, safeguards against addiction and the misuse of
drugs mean that patients with prescriptions for unlicensed
medicines, such as medicinal cannabis, need to have their
prescription reviewed every 30 days by specialist doctors.
This can lead to delays in treatment if there are also delays
to imports.
The new measures will be implemented by the Home Office and
the Medicines and Healthcare products Regulatory Agency
(MHRA) from 2 March.
It follows the law change in October 2018 to allow specialist
doctors to prescribe cannabis-based products for medicinal
use where clinically appropriate in the UK.
The government is working with industry to explore further
ways to reduce costs and encourage more research into
uninterrupted access to cannabis-based medicinal products
where clinically appropriate.
The government will also continue to engage with medical
associations and patients to build evidence, using trials in
the UK to accelerate our understanding of how medicinal
cannabis can benefit patients. This is necessary for wider
prescribing by NHS clinicians in future.
In November last year, the National Institute for Health and
Care Excellence (NICE) recommended 2 cannabis-based medicinal
products for patients with multiple sclerosis and
hard-to-treat epilepsies.
The Department of Health and Social Care continues to work
closely with NHS England-NHS Improvement (NHSE-I) and the
National Institute of Health Research (NIHR) to establish
clinical trials to develop the evidence-base to support
further commissioning decisions.
Health and Social Care Secretary said:
Every time I meet the families of young people dealing so
bravely with childhood epilepsy, I am reminded of just how
much they have been through.
The changes made today are a tremendous step towards
improving the supply of cannabis-based medicinal products
by helping to ensure quicker and more reliable access for
patients.
But we still have a long way to go. We need more research
into the quality and safety of these medicines, and to do
all we can to cut down the costs and remove barriers so
that, when appropriate, patients can access it, including
on the NHS.
Home Secretary said:
I have taken swift action to allow specialist doctors to
issue prescriptions for cannabis-based medicinal products,
when they consider their patients would benefit from this
treatment.
This will allow patients and their families with
challenging conditions to access them more easily, when
appropriate, to ensure they can be treated in days, not
months.